THE LATEST FROM IPC, INDUSTRY, AND NEWS
The safety of treatment for immune-mediated diseases like psoriasis during the COVID-19 pandemic is a matter of concern. In an Israeli population-based nested case-control study using the Clalit Health Services database, 3,151 patients with psoriasis that tested positive for SARS-CoV-2 infection were identified.
Because of the growing body of evidence indicating sex differences in the clinical outcomes of coronavirus disease 2019 (COVID-19) infection, the IMPACT Research Team from Yale University investigated sex differences in viral loads, SARS-CoV-2-specific antibody titers, plasma cytokines, as well as blood cell phenotyping in COVID-19 patients.
An article recently published in the Journal of Allergy and Clinical Immunology suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1,115 of whom had been diagnosed with COVID-19.
In a recent publication in Nature Communications1 a team from Friedrich-Alexander University in Germany described their findings from a cross-sectional population cohort study on the prevalence of anti-SARS-CoV-2 immunoglobulin G (IgG) in patients with chronic immune-mediated inflammatory diseases (IMIDs) on cytokine-blocking treatments.
Held virtually on December 11 due to the Coronavirus Pandemic, the 2020 IPC Think Tank convened more than 100 specialists in psoriasis and industry partners from all over the world to discuss the most pressing issues affecting psoriasis care and treatment globally. The outcome of these discussions will inform IPC initiatives in 2021 and beyond.
Recently, the Task Force (TF) of the National Psoriasis Foundation (NPF) released a revised version of its COVID-19 statement after an in-depth analysis of publicly available data with two currently approved anti-SARS-CoV-2 vaccines in the US, both mRNA-based.
The SARS-CoV-2 pandemic continues to have a considerable impact on the provision of appropriate care to people with psoriasis.
The IPC Disease Severity Working Group concluded that the objective measures of two commonly used clinical tools to determine psoriasis severity may not fully capture the impact of the disease on the individual in a new review published in the Journal of The Academy of Dermatology and Venerology (JEADV).